Chlorhexidine gluconate soap + Chlorhexidine gluconate oral rinse + Mupirocin calcium 2 % ointment
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedAbout Chlorhexidine gluconate soap + Chlorhexidine gluconate oral rinse + Mupirocin calcium 2 % ointment
Chlorhexidine gluconate soap + Chlorhexidine gluconate oral rinse + Mupirocin calcium 2 % ointment is a approved stage product being developed by Johnson & Johnson for MRSA. The current trial status is completed. This product is registered under clinical trial identifier NCT02029872. Target conditions include MRSA.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02029872 | Approved | Completed |
Competing Products
4 competing products in MRSA
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| linezolid (Zyvox) + vancomycin | Pfizer | Approved | 84 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 22 |
| Vancomycin inhalation powder + Placebo inhalation powder + Vancomycin inhalation powder | Savara | Phase 3 | 72 |
| EDP-322 | Enanta Pharmaceuticals | Phase 1 | 25 |